A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis - Concepedia

Concepedia

Publication | Closed Access

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

77

Citations

13

References

2016

Year

Robert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort, Shawnta Jackson, Haifeng Zhang, Robert Flores, Robert Newton, Peggy Scherle, Swamy Yeleswaram, Xuejun Chen,

Journal of Dermatological Treatment

Abstract

INCB039110 produced significant improvements in sPGA, demonstrating proof of concept in chronic plaque psoriasis.

References

	Year	Citations

Page 1